secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001628908-26-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q4 2025 revenue $468.7M, net loss $429.1M; guides 2026 revenue up ~30%
------------------------------------------------------------------------------

- Q4 2025 revenue $468.7M, full-year $1.876B. Net loss $429.1M Q4, $579.4M full year.
- Adjusted EBITDA $37.8M (8.1% margin) Q4; $151.2M (8.1% margin) full year.
- Performance Suite average members 6,482 for year; $900M new Performance Suite revenue for 2026.
- 2026 revenue growth guidance ~30%; first-half Adj. EBITDA pressured by reservering and membership declines.
- Medical expense ratio 90.2% Q4; 80.5% full year (excl. ECP 94.8% and 89.0%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890826000014/0001628908-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890826000014/evh-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001628908-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer